CD82 · Western blot design guide

CD82 Western Blot Planning Guide

Plan a CD82 Western blot around the catalog-observed 29.6 kDa band, image-backed PB9170 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for CD82 (CD82): expected band 29.6 kDa, antibody PB9170, and guide-derived SDS-PAGE protocol steps
CD82 Western blot protocol sheet — expected band 29.6 kDa, antibody PB9170, controls and PMC citations. Open the full CD82 WB guide →

CD82 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 29.6 kDa
Observed band Not reported — verify product WB image
Gel 12-15%
Positive control ⓘ Placenta
Negative control ⓘ Bone marrow
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 29.6 kDa
ⓘ Localization Cell membrane / Cytoplasmic vesicle, phagosome
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human
Section 1

Real Curated CD82 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysatePlacenta
Gel %12-15%
Load20-30 µg total protein per lane
TransferSemi-dry, short transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9170 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected CD82 Western Blot Band Size?

Use the product-observed 29.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
29.6 kDaMatches the authoritative product WB observation.
29.6 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected CD82 appearancePlan around 29.6 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band29.6 kDa; use this as the primary experimental expectation.
Calculated mass29.6 kDa from UniProt P27701; retain as context.
Gel selection12-15%; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9170.
Why is my band missing or off?
SituationLikely causeNext action
29.6 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for CD82 Western blot

🧪Use Placenta as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Placenta (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for CD82

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Placenta Reported tissue cells High Protein (HPA) HPA →
Esophagus Reported tissue cells Medium Protein (HPA) HPA →
Kidney Reported tissue cells Medium Protein (HPA) HPA →
Appendix Reported tissue cells Medium Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Bone marrow Reported tissue cells Not detected Protein (HPA) HPA →
Bronchus Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced CD82 Western Blot Tips

Deeper troubleshooting and optimisation questions for CD82, answered from its protein features.

Which band should guide the blot?
Use 29.6 kDa, the observation attached to the authoritative PB9170 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 29.6 kDa expectation.
Which positive control should I start with?
Start with Placenta, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 12-15% consistently across the quick facts, protocol table, and poster.
What transfer method to use for CD82 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9170 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

CD82 Western Blot Reagents

Human-reactive CD82 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for CD82 using PB9170; observed band 29.6 kDa
Anti-CD82 Antibody Picoband®
Cat # PB9170

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt P27701
  2. Human Protein Atlas — CD82
  3. PB9170 product record
  4. PMC9828285 — CD82 palmitoylation site mutations at Cys5+Cys74 affect EGFR internalization and metabolism through recycling pathway (Acta biochimica et biophysica Sinica, 2022)
  5. PMC7654213 — CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate Cancer (Disease markers, 2020)
  6. PMC10969677 — A Potential Role of CD82/KAI1 during Uterine Decidualization in Mice (Current issues in molecular biology, 2024)